Emil R. Sabitov
Emil R. Sabitov has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
- Evgeniya S. Kuzmina
Oncology Center No. 1 of the City Clinical Hospital named after S. S. Yudin of the Moscow Department of Health
3 shared publications - Ilya A. Pokataev
Oncology Center No. 1 of the City Clinical Hospital named after S. S. Yudin of the Moscow Department of Health
3 shared publications - Magomed M. Dolov
European Medical Center
3 shared publications - Margarita V. Nosova
Yudin Moscow City Clinical Hospital
3 shared publications - Olesia A. Stativko
Oncology Center No. 1 of the City Clinical Hospital named after S. S. Yudin of the Moscow Department of Health
3 shared publications - Sergey A. Kravtsov
Oncological Center No. 1, branch of Moscow City Hospital named after S.S. Yudin
3 shared publications
Latest Publications
- Open Access
- 3 November 2025
- Published by Publishing House ABV Press in Head and Neck Tumors (HNT)
- Vol. 15 (3) , 65-74
Surgical correction of nutritional status as an element of an integrated approach in the treatment and rehabilitation of patients with malignant tumors of the head and neck organs
Introduction. A significant proportion of patients with malignant neoplasms of the head and neck have protein and energy deficiency, which is associated with the localization of the tumor in close proximity to the proximal digestive tract, its aggressive growth, the presence of complications of the tumor process, as well as drug and / or radiation treatment. If there is a violation of the full replenishment of the need for nutrients in a natural way, the need for longterm nutritional support at the stages of antitumor treatment and the preservation of the function of the gastrointestinal tract, the method of choice is the formation of a gastrostomy. In addition to the effects of its direct purpose, gastrostomy promotes social adaptation of patients, as well as eliminates the risks associated with the installation and prolonged use of a nasogastric tube, and is compatible with other surgical procedures at the stages of antitumor treatment, symptomatic and palliative care.Aim. To evaluate the clinical and social significance of performing gastrostomy in patients with squamous cell carcinoma of the head and neck.Materials and methods. The present study included 150 patients with squamous cell carcinoma of the head and neck organs who underwent minimally invasive gastrostomy (133 / 150; 88.7 %), open-label (11 / 150; 7.3 %) or interventional under CT control (6 / 150; 4 %). In 88 (58.7 %) patients, gastrostomy was combined with other medical procedures (tumor biopsy, tracheostomy, selective intraarterial embolization). Descriptive statistics methods and the t-test were used to evaluate the results of the study. The differences were considered significant at p 0.05.Results. Postoperative complications were observed in 12.7 % of patients, hospital mortality was 2 %. The average length of stay of patients in the hospital with uncomplicated course of the postoperative period was 7.1 ± 5.0 days, in the presence of complications – 18.2 ± 18.5 days. Among patients receiving antitumor treatment after gastrostomy drainage, the median time between gastrostomy and its onset was 20 days, and the median overall survival was 261.5 days. for patients under medical supervision, the median overall survival reached 621 days. This indicator in patients who did not receive antitumor treatment after gastrostomy and patients referred to the palliative Care Center was 52 and 61 days, respectively.Conclusion. performing gastrostomy in a minimally invasive manner is an essential component of the prehabilitation of debilitated patients with complicated squamous cell carcinoma of the head and neck organs. This manipulation allows you to start or resume antitumor treatment, as well as increase overall survival.
- 3 November 2025
- Published by Publishing House ABV Press in Head and Neck Tumors (HNT)
- Vol. 15 (3) , 65-74
Open AccessSurgical correction of nutritional status as an element of an integrated approach in the treatment and rehabilitation of patients with malignant tumors of the head and neck organs
Introduction. A significant proportion of patients with malignant neoplasms of the head and neck have protein and energy deficiency, which is associated with the localization of the tumor in close proximity to the proximal digestive tract, its aggressive growth, the presence of complications of the tumor process, as well as drug and / or radiation treatment. If there is a violation of the full replenishment of the need for nutrients in a natural way, the need for longterm nutritional support at the stages of antitumor treatment and the preservation of the function of the gastrointestinal tract, the method of choice is the formation of a gastrostomy. In addition to the effects of its direct purpose, gastrostomy promotes social adaptation of patients, as well as eliminates the risks associated with the installation and prolonged use of a nasogastric tube, and is compatible with other surgical procedures at the stages of antitumor treatment, symptomatic and palliative care.Aim. To evaluate the clinical and social significance of performing gastrostomy in patients with squamous cell carcinoma of the head and neck.Materials and methods. The present study included 150 patients with squamous cell carcinoma of the head and neck organs who underwent minimally invasive gastrostomy (133 / 150; 88.7 %), open-label (11 / 150; 7.3 %) or interventional under CT control (6 / 150; 4 %). In 88 (58.7 %) patients, gastrostomy was combined with other medical procedures (tumor biopsy, tracheostomy, selective intraarterial embolization). Descriptive statistics methods and the t-test were used to evaluate the results of the study. The differences were considered significant at p 0.05.Results. Postoperative complications were observed in 12.7 % of patients, hospital mortality was 2 %. The average length of stay of patients in the hospital with uncomplicated course of the postoperative period was 7.1 ± 5.0 days, in the presence of complications – 18.2 ± 18.5 days. Among patients receiving antitumor treatment after gastrostomy drainage, the median time between gastrostomy and its onset was 20 days, and the median overall survival was 261.5 days. for patients under medical supervision, the median overall survival reached 621 days. This indicator in patients who did not receive antitumor treatment after gastrostomy and patients referred to the palliative Care Center was 52 and 61 days, respectively.Conclusion. performing gastrostomy in a minimally invasive manner is an essential component of the prehabilitation of debilitated patients with complicated squamous cell carcinoma of the head and neck organs. This manipulation allows you to start or resume antitumor treatment, as well as increase overall survival.
- Open Access
- 22 January 2025
- Published by Russian Society of Clinical Oncology in Malignant tumours
- Vol. 14 (4) , 29-36
Comparative analysis of induction chemotherapy followed by chemoradiotherapy and concurrent chemoradiation therapy efficacy in patients with locally advanced head and neck squamous cell cancer
Treatment strategy of advanced unresectable head and neck squamous cell cancer (HNSCC) is limited to induction chemotherapy (ICT) followed by (chemo) radiotherapy (cRT) and concurrent chemoradiotherapy (CCRT). However, the role of ICT remains controversial considering the lack of overall survival benefit.The aim: to evaluate the role of induction chemotherapy in the treatment of locally advanced HNSCC.Methods: We performed a retrospective clinical study that included patients (pts) with unresectable stage III–IVa cancer of larynx, oropharynx and hypopharynx.Results: A total of 176 pts were enrolled, 84 (48 %) received CCRT with cisplatin or carboplatin and 92 (52 %) — ICT followed by cRT. Groups were well balanced by sex, tumor site, T-stage, while in group of ICT there was a significant prevalence of younger pts (p = 0.004) and pts with stage N2–3 (p = 0,03).The objective response rates (ORR) were 76 % (42 / 55) in CCRT arm (including 53 % (12 / 62) of complete responses) and 72 % (56 / 78) in ICT arm with complete response rate of 15 % (12 / 78). The ORR in ICT arm increased after the completion of CCRT up to 82 % with 53 % (33 / 62) of complete responses. The difference was not statistically significant (p = 0,7).With a median follow-up duration of 8.7 months median progression-free survival (mPFS) was 7.6 and 9.4 months (Hazard ratio (HR) 0.67, 95 % CI 0.43–1.04); 6month OS was 65.7 % and 92.8 % in CCRT and ICT groups, respectively (HR 0.51, 95 % CI 0.30–0.85, р < 0.01).Propensity score matching analysis proved the 6month OS in the ICT + cRT group to be significantly longer than in CCRT group — 97.7 % vs 66.8 %, respectively (HR = 0.28, 95 % CI 0.13–0.62, p < 0.01).Conclusions: ICT + сRT resulted in improvement of PFS and OS compared to CCRT in pts with locally advanced HNSCC.
- 22 January 2025
- Published by Russian Society of Clinical Oncology in Malignant tumours
- Vol. 14 (4) , 29-36
Open AccessComparative analysis of induction chemotherapy followed by chemoradiotherapy and concurrent chemoradiation therapy efficacy in patients with locally advanced head and neck squamous cell cancer
Treatment strategy of advanced unresectable head and neck squamous cell cancer (HNSCC) is limited to induction chemotherapy (ICT) followed by (chemo) radiotherapy (cRT) and concurrent chemoradiotherapy (CCRT). However, the role of ICT remains controversial considering the lack of overall survival benefit.The aim: to evaluate the role of induction chemotherapy in the treatment of locally advanced HNSCC.Methods: We performed a retrospective clinical study that included patients (pts) with unresectable stage III–IVa cancer of larynx, oropharynx and hypopharynx.Results: A total of 176 pts were enrolled, 84 (48 %) received CCRT with cisplatin or carboplatin and 92 (52 %) — ICT followed by cRT. Groups were well balanced by sex, tumor site, T-stage, while in group of ICT there was a significant prevalence of younger pts (p = 0.004) and pts with stage N2–3 (p = 0,03).The objective response rates (ORR) were 76 % (42 / 55) in CCRT arm (including 53 % (12 / 62) of complete responses) and 72 % (56 / 78) in ICT arm with complete response rate of 15 % (12 / 78). The ORR in ICT arm increased after the completion of CCRT up to 82 % with 53 % (33 / 62) of complete responses. The difference was not statistically significant (p = 0,7).With a median follow-up duration of 8.7 months median progression-free survival (mPFS) was 7.6 and 9.4 months (Hazard ratio (HR) 0.67, 95 % CI 0.43–1.04); 6month OS was 65.7 % and 92.8 % in CCRT and ICT groups, respectively (HR 0.51, 95 % CI 0.30–0.85, р < 0.01).Propensity score matching analysis proved the 6month OS in the ICT + cRT group to be significantly longer than in CCRT group — 97.7 % vs 66.8 %, respectively (HR = 0.28, 95 % CI 0.13–0.62, p < 0.01).Conclusions: ICT + сRT resulted in improvement of PFS and OS compared to CCRT in pts with locally advanced HNSCC.
- Open Access
- 22 January 2025
- Published by Autonomous non-profit scientific and medical organization - Questions of Oncology in Voprosy onkologii
- Vol. 70 (6)
Toxicity and Safety of Induction Chemotherapy in Locally Advanced Oropharynx, Hypopharynx and Larynx: Non-Randomized Study Comparing DCF and Immunochemotherapy (ICT) with PF-Pembrolizumab
Введение. Стандартный режим индукционной химиотерапии по схеме DCF характеризуется высокой частотой объективного ответа у пациентов с распространенными опухолями головы и шеи. Высокая токсичность режима ограничивает возможность его применения. Проспективное нерандомизированное исследование оценивает эффективность и безопасность иммунохимиотерапии (ИХТ) в качестве индукции. Цель. В этой работе представлены данные сравнения безопасности режима DCF и PF — пембролизумаб, а также риски отказа или незавершения последующей химиолучевой терапии (ХЛТ). Методы. В проспективное нерандомизированное исследование II фазы включались пациенты с III-IV стадией плоскоклеточного местнораспространенного рака ротоглотки, гортани, гортаноглотки в случае положительной экспрессии PD-L1 в опухоли (CPS>=1). Пациентам проводились 3 цикла ИХТ пембролизумабом, цисплатином и 5-фторурацилом с последующим проведением ХЛТ. Группа контроля была оценена ретроспективно. В неё включались пациенты, которые в этот же период времени получали режим DCF (доцетаксел + цисплатин + 5-фторурацил) с последующим проведением ХЛТ. Результаты. В период с апреля 2022 г. по июль 2024 г. включено 120 пациентов для проведения ИХТ. Контрольная группа включила данные по 115 пациентам. Частота нежелательных явлений 3-5 степени составила 30 % и 30,4 % для группы ИХТ и группы DCF (p = 1,00). На этапе индукционной терапии отмечено 6 случаев смерти (5,2 %) в группе DCF, в группе пембролизумаб-PF летальных случаев на этапе индукционной терапии не было (р = 0,01). Высокая доза цисплатина в группе ИХТ ассоциирована с более значимой тенденцией к снижению скорости клубочковой фильтрации (СКФ), в сравнении с группой DCF. Медиана снижения составила СКФ 10,5 %. Во всех случаях снижение СКФ не привело к необходимости проведения гемодиализа. В группе ИХТ 4 пациентам (3,3 %) не проведена лучевая терапия в связи с общим ухудшением здоровья на фоне индукционной терапии, в группе DCF — 12 пациентам (10 %), p = 0,06. Заключение. Индукционный режим PF-пембролизумаб обладает приемлемым профилем токсичности. Дальнейшее изучение эффективности ИХТ представляется актуальной задачей. Исследование зарегистрировано на портале clinicaltrials.gov (номер NCT05551767).
- 22 January 2025
- Published by Autonomous non-profit scientific and medical organization - Questions of Oncology in Voprosy onkologii
- Vol. 70 (6)
Open AccessToxicity and Safety of Induction Chemotherapy in Locally Advanced Oropharynx, Hypopharynx and Larynx: Non-Randomized Study Comparing DCF and Immunochemotherapy (ICT) with PF-Pembrolizumab
Введение. Стандартный режим индукционной химиотерапии по схеме DCF характеризуется высокой частотой объективного ответа у пациентов с распространенными опухолями головы и шеи. Высокая токсичность режима ограничивает возможность его применения. Проспективное нерандомизированное исследование оценивает эффективность и безопасность иммунохимиотерапии (ИХТ) в качестве индукции. Цель. В этой работе представлены данные сравнения безопасности режима DCF и PF — пембролизумаб, а также риски отказа или незавершения последующей химиолучевой терапии (ХЛТ). Методы. В проспективное нерандомизированное исследование II фазы включались пациенты с III-IV стадией плоскоклеточного местнораспространенного рака ротоглотки, гортани, гортаноглотки в случае положительной экспрессии PD-L1 в опухоли (CPS>=1). Пациентам проводились 3 цикла ИХТ пембролизумабом, цисплатином и 5-фторурацилом с последующим проведением ХЛТ. Группа контроля была оценена ретроспективно. В неё включались пациенты, которые в этот же период времени получали режим DCF (доцетаксел + цисплатин + 5-фторурацил) с последующим проведением ХЛТ. Результаты. В период с апреля 2022 г. по июль 2024 г. включено 120 пациентов для проведения ИХТ. Контрольная группа включила данные по 115 пациентам. Частота нежелательных явлений 3-5 степени составила 30 % и 30,4 % для группы ИХТ и группы DCF (p = 1,00). На этапе индукционной терапии отмечено 6 случаев смерти (5,2 %) в группе DCF, в группе пембролизумаб-PF летальных случаев на этапе индукционной терапии не было (р = 0,01). Высокая доза цисплатина в группе ИХТ ассоциирована с более значимой тенденцией к снижению скорости клубочковой фильтрации (СКФ), в сравнении с группой DCF. Медиана снижения составила СКФ 10,5 %. Во всех случаях снижение СКФ не привело к необходимости проведения гемодиализа. В группе ИХТ 4 пациентам (3,3 %) не проведена лучевая терапия в связи с общим ухудшением здоровья на фоне индукционной терапии, в группе DCF — 12 пациентам (10 %), p = 0,06. Заключение. Индукционный режим PF-пембролизумаб обладает приемлемым профилем токсичности. Дальнейшее изучение эффективности ИХТ представляется актуальной задачей. Исследование зарегистрировано на портале clinicaltrials.gov (номер NCT05551767).
- Open Access
- 18 December 2024
- Published by Consilium Medicum in Journal of Modern Oncology
- Vol. 26 (4) , 447-453
First results of a multicenter, non-randomized, prospective phase II study of the efficacy and safety of induction therapy with pembrolizumab, cisplatin, and 5-fluorouracil in patients with unresectable squamous cell carcinoma of the oropharynx, hypopharynx and larynx
Background. The approved regimen of induction chemotherapy with docetaxel + cisplatin + 5-fluorouracil has high risk of unacceptable toxicity for many patients with advanced head and neck cancer (HNSCC). Toxicity can also compromise the delivery of the following chemoradiation. In order to improve the results of these pts treatment we conducted a prospective multicenter non-randomized phase II study of induction immunochemotherapy followed by (chemo)radiation and here we report first results of objective response rate (ORR), the safety profile of induction therapy and risk of further radiation therapy omission (NCT05551767). Materials and methods. The inclusion criteria were: unresectable stage III–IVA cancer of larynx, oropharynx, hypopharynx, PD-L1-positive (CPS≥1) squamous cell cancer, ECOG 0-2. Included pts received 3 cycles of pembrolizumab 200 mg d1+ cisplatin 100 mg/m2 d1 + 5-fluorouracil 1000 mg/m2/day 1-4 d followed by (chemo-) radiation. Results. Since January 2022 a total of 120 pts were included. Median age was 60 (35–75), the majority were male (105; 87.5%). Objective responses were assessed in 116 of 120 pts. ORR on induction phase was 62.9% (n=73), including 16.4% (n=19) of complete responses. Median change of target lesions was -55% (from -100% to 65%). To date, only 7 pts did not start (chemo)radiation in time due to disease progression (4 pts) or refuse of consent (3 pts). Among 95 pts who completed radiation therapy 94.7% received radiation dose ≥66Gy. The incidence of grade 3-4 adverse events was 30,8%, in 6 (5%) pts it required hospitalization. No grade 5 adverse events were observed. The most common toxicity was hematological with neutropenia grade 3-4 in 28 (23.3%) pts. There was mild immune-related toxicity: 2 (1.7%) pts had skin rash and 1 (0.8%) – hypothyroidism. The use of high dose of cisplatin resulted in a trend to decline glomerular filtration rate (median decrease was 10.5% from baseline) although none of pts required hemodialysis. Conclusion. Induction therapy with pembrolizumab plus cisplatin and 5-fluorouracil provided meaningful ORR and acceptable safety profile in locally advanced HNSCC. It almost did not influence the following radiation therapy omission rate. Further follow-up is needed to assess long-term efficacy.
- 18 December 2024
- Published by Consilium Medicum in Journal of Modern Oncology
- Vol. 26 (4) , 447-453
Open AccessFirst results of a multicenter, non-randomized, prospective phase II study of the efficacy and safety of induction therapy with pembrolizumab, cisplatin, and 5-fluorouracil in patients with unresectable squamous cell carcinoma of the oropharynx, hypopharynx and larynx
Background. The approved regimen of induction chemotherapy with docetaxel + cisplatin + 5-fluorouracil has high risk of unacceptable toxicity for many patients with advanced head and neck cancer (HNSCC). Toxicity can also compromise the delivery of the following chemoradiation. In order to improve the results of these pts treatment we conducted a prospective multicenter non-randomized phase II study of induction immunochemotherapy followed by (chemo)radiation and here we report first results of objective response rate (ORR), the safety profile of induction therapy and risk of further radiation therapy omission (NCT05551767). Materials and methods. The inclusion criteria were: unresectable stage III–IVA cancer of larynx, oropharynx, hypopharynx, PD-L1-positive (CPS≥1) squamous cell cancer, ECOG 0-2. Included pts received 3 cycles of pembrolizumab 200 mg d1+ cisplatin 100 mg/m2 d1 + 5-fluorouracil 1000 mg/m2/day 1-4 d followed by (chemo-) radiation. Results. Since January 2022 a total of 120 pts were included. Median age was 60 (35–75), the majority were male (105; 87.5%). Objective responses were assessed in 116 of 120 pts. ORR on induction phase was 62.9% (n=73), including 16.4% (n=19) of complete responses. Median change of target lesions was -55% (from -100% to 65%). To date, only 7 pts did not start (chemo)radiation in time due to disease progression (4 pts) or refuse of consent (3 pts). Among 95 pts who completed radiation therapy 94.7% received radiation dose ≥66Gy. The incidence of grade 3-4 adverse events was 30,8%, in 6 (5%) pts it required hospitalization. No grade 5 adverse events were observed. The most common toxicity was hematological with neutropenia grade 3-4 in 28 (23.3%) pts. There was mild immune-related toxicity: 2 (1.7%) pts had skin rash and 1 (0.8%) – hypothyroidism. The use of high dose of cisplatin resulted in a trend to decline glomerular filtration rate (median decrease was 10.5% from baseline) although none of pts required hemodialysis. Conclusion. Induction therapy with pembrolizumab plus cisplatin and 5-fluorouracil provided meaningful ORR and acceptable safety profile in locally advanced HNSCC. It almost did not influence the following radiation therapy omission rate. Further follow-up is needed to assess long-term efficacy.